BioNTech : 2022 Sustainability Report

SUSTAINABILITY REPORT 2022

" Our core values form the basis of everything

we do: we are innovative, passionate and united. Throughout our work we are committed to being transparent, acting with integrity, protecting the environment and respec-ting human rights. These principles serve as the constant foundation for our work and, most import-antly, for our very own expectations of ourselves.

BioNTech at a Glance

OUR VALUES

A 21ST CENTURY IMMUNOTHERAPY POWERHOUSE

united

passionateinnovative

Fully integrated biotechnology company

Multi-platform strategy

Diversified product pipeline

Based on global social responsibility: → Focused on high medical needs

→

Democratizing access to novel medicine and technological innovation in healthcare

3

CLIMATE PROTECTION

SOCIAL 4

FINANCIALS

1.5°C

On

pathway

(submitted for SBTi validation)

4,692

employees from over

Women in highest management level below Management Board

80nations

38

Total revenues in 2022 financial year in €

17.3 billionNet profit in 2022 financial year in €

9.4 billion

Contents

OUR PURPOSE

• 1.0 About BioNTech6

• 2.0 Our Responsibility15

  BioNTech was founded in Mainz, Germany, in 2008 with the under-standing that each cancer patient's tumor is unique and the vision that each patient's treatment should be individualized. To turn this idea into reality, we have combined innovative research with cutting-edge technologies.

• 3.0 Corporate Citizenship23

• 4.0 Responsible Governance29

• 5.0 Environmental & Climate Protection51

  Our objective is to develop breakthrough therapies against cancer, infectious diseases and other serious diseases.

• 6.0 Attractive Employer64

• 7.0 ESG Ratings & Memberships77

• 8.0 Appendix & Data81

INTERACTIVE PDF

As a next-generation immunotherapy company, we are working to clinically prove the benefits of our treatment approach. Our COVID-19 vaccine is an important milestone. We are continuously expanding our collaborations, our team and our own manufacturing capabilities with the aim of providing individualized treatments to patients around the world.

4

Optimized for display with Adobe Acrobat. This PDF document is optimized for use on screen. You can jump to the desired content by clicking on the information in the tables of contents, the headings in the headers, or on page references and links in the graphs and tables.

Navigation buttonsSearch

References in the text

Table of contents

Page referenceWebsite

Chapter table of contents

Page back

We are accelerating the development of our diversified pipeline of next-generation immunotherapies, aspiring to improve the health of people worldwide by harnessing the full potential of the immune system. In addition to cancer, infectious diseases and other serious diseases, this includes autoimmune diseases, allergies and regener-ative medicine.

Page forwardPrevious page view

Dear Reader,

In developing novel medicines and introducing scalable techno-logical innovation, we are driven by our vision to improve the health of people worldwide. We plan to accelerate the build-out of our oncology commercial capabilities in 2023-24 with the goal of commercial readiness in the United States, European Union and other selected regions to seek approval for multiple oncology products from 2026 onwards. Longer term, we see applications for our technologies in the fields of autoimmune diseases, inflammatory diseases, cardiovascular diseases, neurodegenera-tive diseases, and regenerative medicines.

This pioneering spirit, our research, and our innovative power are fundamental to developing innovative medicines as our most important and greatest social contribution to society. BioNTech was founded on this commitment 15 years ago, and it remains the foundation of our research and core business today.

We therefore rightly place such achievements at the very begin-ning of our third sustainability report:

• → Our globally successful marketed COVID-19 vaccines, includ-ing the first-to-market Original/Omicron BA.4-5-adapted bivalent vaccine, have been making a significant contribution to people and societies worldwide.

• → Our focus on addressing high unmet medical needs, espe-cially through the development of potential cancer therapies and vaccines against some of the world's most common infec-tious diseases.

• → The introduction of our BioNTainer, a flexible container solu-tion that provides turnkey mRNA production facilities for scal-able, local vaccine production, aiming to facilitate equitable access to medicines in healthcare. The first six containers for the first BioNTainer arrived in Kigali, Rwanda, in March 2023.

These developments and our substantial growth - exemplified by our creation of approximately 1,500 new jobs in 2022 - are changing our organization and our stakeholders' expectations. As the Management Board, we plan to continuously strengthen our research and core business through our sustainable development strategy.

We have reinforced our CSR team, built up sustainability resources in business units, and further developed sustainability competen-cies at the Supervisory Board, Management Board and manage-ment levels, as well as in our operations. We will continue to drive forward our efforts to integrate sustainability risks into our corpo-rate risk management in 2023.

This sustainability report provides structured information on the development of our strategically most important sustainability projects in 2022.

Significant progress was made in our human rights and climate protection management. Information on business continuity and information security was added and expanded. In the chapter "Attractive Employer", we describe how we create a culture and environment that promotes the full potential of all employees.

We could not have accomplished all our achievements without our employees. We deeply thank them for their passion and endur-ance, for their courage and will to overcome hurdles and obstacles, and for their strength and ability to make things happen.GRI 2-22

5